Abstract
Background: Metformin use has been reported to reduce cancer risk, and improve survival in lung cancer patients. This study aimed to investigate the effect of metformin use among patients with lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) therapy. Patients and Methods: A nationwide, population-based case-control study was conducted using the Taiwan National Health Insurance Research Database. From January 1, 2004 to December 31, 2012, a total of 373 metformin and 1,260 non-metformin lung cancer cohorts with diabetes mellitus and EGFR-TKIs treatment were studied. Results: Metformin use was significantly associated with a reduced risk of death (HR: 0.73, 95% CI: 0.62-0.85, p Conclusion: In conclusion, metformin might potentially enhance the therapeutic effect and increase survival in patients with lung cancer receiving EGFR-TKI therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
